Cargando…

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials

Currently, there are more than 30 million people infected with HIV-1 and thousands more are infected each day. Vaccination is the single most effective mechanism for prevention of viral disease, and after more than 25 years of research, one vaccine has shown somewhat encouraging results in an advanc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brown, Scott A., Surman, Sherri L., Sealy, Robert, Jones, Bart G., Slobod, Karen S., Branum, Kristen, Lockey, Timothy D., Howlett, Nanna, Freiden, Pamela, Flynn, Patricia, Hurwitz, Julia L.
Formato:	Texto
Lenguaje:	English
Publicado:	Molecular Diversity Preservation International (MDPI) 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855973/ https://www.ncbi.nlm.nih.gov/pubmed/20407589 http://dx.doi.org/10.3390/v2020435

Ejemplares similares

Clade, Country and Region-specific HIV-1 Vaccines: Are they necessary?
por: Slobod, Karen S, et al.
Publicado: (2005)

Potency of an HIV-SAM™ vaccine in a heterologous prime-boost vaccination regimen
por: Banerjee, K, et al.
Publicado: (2012)

Respiratory Syncytial Virus: Current Progress in Vaccine Development
por: Rudraraju, Rajeev, et al.
Publicado: (2013)

The efficacy of the prime-boost regimen for heterologous infectious bronchitis vaccines mandates the administration of homologous vaccines
por: Al-Kubati, Anwar A. G., et al.
Publicado: (2022)

Heterologous prime boost COVID 19 vaccination
por: Launay, O., et al.
Publicado: (2022)

Might Routine Vitamin A Monitoring in Cystic Fibrosis Patients Reduce Virus-Mediated Lung Pathology?
por: Sealy, Robert E., et al.
Publicado: (2021)

Nuclear Receptors, Ligands and the Mammalian B Cell
por: Jones, Bart G., et al.
Publicado: (2020)

Respiratory Tract Epithelial Cells Express Retinaldehyde Dehydrogenase ALDH1A and Enhance IgA Production by Stimulated B Cells in the Presence of Vitamin A
por: Rudraraju, Rajeev, et al.
Publicado: (2014)

Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine
por: Munseri, P, et al.
Publicado: (2012)

Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal
por: Venkatraman, Navin, et al.
Publicado: (2019)

Heterologous Prime-Boost Combinations Highlight the Crucial Role of Adjuvant in Priming the Immune System
por: Ciabattini, Annalisa, et al.
Publicado: (2018)

In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variant
por: Heinen, Natalie, et al.
Publicado: (2022)

Will Attention by Vaccine Developers to the Host’s Nuclear Hormone Levels and Immunocompetence Improve Vaccine Success?
por: Sealy, Robert E., et al.
Publicado: (2019)

Heterologous Prime-Boost Regimens Using rAd35 and rMVA Vectors Elicit Stronger Cellular Immune Responses to HIV Proteins Than Homologous Regimens
por: Ratto-Kim, Silvia, et al.
Publicado: (2012)

Heterologous prime-boost regimens with HAdV-5 and NDV vectors elicit stronger immune responses to Ebola virus than homologous regimens in mice
por: Zhao, Wei, et al.
Publicado: (2021)

Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates
por: Bolton, Diane L., et al.
Publicado: (2012)

Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol
por: Sablerolles, Roos S. G., et al.
Publicado: (2021)

Consequences of Vitamin A Deficiency: Immunoglobulin Dysregulation, Squamous Cell Metaplasia, Infectious Disease, and Death
por: Surman, Sherri L., et al.
Publicado: (2020)

Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen
por: Podola, L, et al.
Publicado: (2012)

Exploring heterologous prime-boost vaccination approaches to enhance influenza control in pigs
por: Li, Chong, et al.
Publicado: (2020)

Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV
por: Chapman, Ros, et al.
Publicado: (2021)

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
por: Nguyen, Thuy Trang, et al.
Publicado: (2022)

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
por: Shaw, Robert H, et al.
Publicado: (2021)

Heterologous prime-boost vaccination against COVID-19: is it safe and reliable?
por: Choudhary, Om Prakash, et al.
Publicado: (2021)

Hyperglycosylated gp120 mutants elicit improved CD4-binding site directed antibodies in a heterologous prime:boost regimen
por: Ahmed, FK, et al.
Publicado: (2012)

Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease
por: Peng, Shiwen, et al.
Publicado: (2016)

Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus
por: Ba, Lei, et al.
Publicado: (2007)

Immune response of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA COVID-19 vaccines in immunocompromised patients
por: Chu, Chang, et al.
Publicado: (2023)

Influences of Vitamin A on Vaccine Immunogenicity and Efficacy
por: Penkert, Rhiannon R., et al.
Publicado: (2019)

Antibody response induced by the boost overdose during COVID-19 heterologous prime-boost vaccination strategy
por: Raposo, Francisco, et al.
Publicado: (2021)

Heterologous prime-boost: an important candidate immunization strategy against Tembusu virus
por: Pan, Yuting, et al.
Publicado: (2020)

Is heterologous prime-boost COVID-19 vaccination a concern or an opportunity for Ethiopia?
por: Gelanew, Tesfaye, et al.
Publicado: (2023)

Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens
por: Crooks, Emma T., et al.
Publicado: (2021)

Reactogenicity after heterologous and homologous COVID-19 prime-boost vaccination regimens: descriptive interim results of a comparative observational cohort study
por: Warkentin, Lisette, et al.
Publicado: (2022)

Heterologous Prime-Boost Vaccination with Commercial FMD Vaccines Elicits a Broader Immune Response than Homologous Prime-Boost Vaccination in Pigs
por: Kim, Jaejo, et al.
Publicado: (2023)

Retinol Binding Protein, Sunlight Hours, and the Influenza Virus-Specific Immune Response
por: Patel, Nehali, et al.
Publicado: (2022)

Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults
por: Scaggs Huang, Felicia, et al.
Publicado: (2020)

rAd5 prime/NYVAC-B boost regimen is superior to NYVAC-B prime/rAd5 boost regimen for both response rates and magnitude of CD4 and CD8 T-cell responses
por: Bart, P, et al.
Publicado: (2012)

Revival of the heterologous prime‐boost technique in COVID‐19: An outlook from the history of outbreaks
por: Siddiqui, Amna, et al.
Publicado: (2022)

How Estrogen, Testosterone, and Sex Differences Influence Serum Immunoglobulin Isotype Patterns in Mice and Humans
por: Surman, Sherri L., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8nas92ondv89u3l1uj1suqshhh